Gavi reaches milestone: one billion children immunised
Gavi reaches milestone: one billion children immunised
1 August 2023
Children at the Peak Kindergarten in Mongolia, photographed for Generation ImmUnity. Credit: Khasar Sandag.
Gavi has now supported the immunisation of more than one billion children with essential vaccines since it was established in 2000.
Gavi has now supported the immunisation of more than one billion children with essential vaccines since it was established in 2000.
This announcement was part of Gavi’s Mid-Term Review report, Raising Generation ImmUnity, which examines data from the first two years of Gavi’s 2021-2025 strategic period. The report showed that Gavi is on track to meet most of the key commitments made to donors. This includes supporting countries to immunise an additional 300 million children by 2025, saving more than seven million lives and generating economic benefits of US$ 80-100 billion.
IFFIm is invested in Gavi’s success, having transferred more than US$ 5.8 billion to Gavi since 2006, making up 18% of the Alliance’s programme funding. This has saved more lives, faster.
The Raising Generation ImmUnity report also showed that after a drop in routine immunisation during the pandemic, vaccination recovered throughout Gavi-supported countries in 2022, though more must be done to reach children who missed out during the pandemic.
Gavi estimates that Immunising over a billion children has prevented more than 17 million future deaths, contributing to halving child mortality in 73 lower-income countries. With vaccine campaigns, full regimen and COVAX, in total, more than six billion doses of vaccines have been provided through Gavi programmes.
Keeping the momentum going, Gavi is on track to exceed 1.1 billion unique children vaccinated through routine immunisation by the end of 2025.
“In the era of polycrises and in the wake of unprecedented disruption due to the pandemic, there will be challenges ahead that we will have to face and overcome together,” said Gavi CEO Dr Seth Berkley. “But that’s exactly what the Vaccine Alliance does best. We work together and pool expertise, partnerships and resources to help countries overcome hurdles in order to leave no one behind with immunisation.”
Read more about Gavi’s progress in 11 key stats from Gavi’s Mid-Term Review.
Share this article
Restricted Access Library
The material in this Restricted Access Library is intended to be accessed only by persons with residence within the territory of a Member State of the European Union and is not intended to be viewed by any other persons. The material in this Restricted Access Library is provided by IFFIm for information purposes only and the materials contained herein were accurate only as of their respective dates. Certain information in the materials contained herein is not intended to be, and is not, current. IFFIm accepts no obligation to update any material contained herein.
Persons with residence outside the territory of a Member State of the European Union who have access to or consult any materials posted in this Restricted Access Library should refrain from any action in respect of the securities referred to in such materials and are otherwise required to comply with all applicable laws and regulations in their country of residence.
By clicking Access restricted content: DYNAMIC-LINK-TEXT I confirm that I have read and understood the foregoing and agree that I will be bound by the restrictions and conditions set forth on this page.
The materials in this Restricted Access Library are for distribution only to persons who are not a "retail client" within the meaning of section 761G of the Corporations Act 2001 of Australia and are also sophisticated investors, professional investors or other investors in respect of whom disclosure is not required under Part 6D.2 of the Corporations Act 2001 of Australia and, in all cases, in such circumstances as may be permitted by applicable law in any jurisdiction in which an investor may be located.
The materials in this Restricted Access Library and any documents linked from it are not for access or distribution in any jurisdiction where such access or distribution would be illegal. All of the securities referred to in this Restricted Access Library and in the linked documents have been sold and delivered. The information contained herein and therein does not constitute an offer for sale in the United States or in any other country. The securities described herein and therein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws.
Each person accessing the Restricted Access Library confirms that they are a person who is entitled to do so under all applicable laws, regulations and directives in all applicable jurisdictions. Neither IFFIm nor any of their directors, employees, agents or advisers accepts any liability whatsoever for any loss (including, without limitation, any liability arising from any fault or negligence on the part of IFFIm or its respective directors, employees, agents or advisers) arising from access to Restricted Access Library by any person not entitled to do so.